| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.sanofiindialtd.com | |
| Market Cap | 15,012.40 Cr. | |
| Enterprise Value(EV) | 13,462.10 Cr. | 2021-12 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 450.23 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | 14.48 | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 28.15 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | 1,043.80 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | 6.24 | Calculated using Price: 6,518.45 |
| Dividend Yield | 7.52 | Period Ending 2021-12 |
| No. of Shares Subscribed | 2.30 Cr. | 23,030,622 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Sanofi India is one of the entities through which Sanofi operates in India. It was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited. Over the years, its name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited, Hoechst Marion Roussel Limited and Aventis Pharma Limited. Sanofi, one of the world's leading healthcare companies, and its 100% subsidiary - Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.4% of its paid-up share capital. The shares of Sanofi India Limited are quoted on the Bombay Stock Exchange and the National Stock Exchange. The company has two manufacturing sites in Ankleshwar and Goa. Sanofi India also manufactures its products through third party manufacturers. The different types of dosage forms include tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams and ointments. These products are manufactured in accordance with the same quality standards as those prevalent at its own manufacturing sites for domestic consumption and for export to Russia, the Ukraine and other CIS countries. Business area of the company The company is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. The company prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. The company stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. Products Pharmaceutical products (Adenocor, Aldurazyme, AllStar, Amaryl, Apidra, Arava, Aubagio, Augeoz, Brodactam, Cardace, Caspercid, Cerezyme, Cetapin, Clexane, Cordarone, Daonil, Depakote, Fabrazyme, Fasturtec, Fludara, Frisium, Insuman, Jevtana, Lantus, Lasilactone, Lasix, Lyxumia, Metosan, M-Nem, Myoril, Myozyme, Plavix, Primacor, Renvela Sachets, Soframycin, Solian, Stilnoct, Synvisc, Targocid, Taxotere, Telsite, Thymoglobuline, Thyrogen, Toujeo, Trental, Valparin, Vinlep, Zemiglo). Vaccines (Adacel, Avaxim, FluQuadri, Hexaxim, Imovax Polio, Menactra, Pentaxim, Shan5, Shanchol, ShanIPV, ShanTT, Shanvac-B, Stamaril, Vaxigrip) Consumer Healthcare products (Allegra, Allegra, Allegra M, Aminofit Forte, Amino-fit, Avil, Baralgan NU, Berrycran, Buscogast, Cetgel, Collaflex, Combiflam Plus, Combiflam Suspension, Combiflam IcyHotTM, Combiflam IcyHotTM spray, CoQ 300, DePURA by Sanofi, Dulcoflex Natural, DulcoSoft Sachet, E-Cod Plus, E-Cod W, Enlarge Forte, Enterogermina, Estoven XT, Festal N, FreeFlex Forte, Icegel, Lactacyd, Macraberin M, Mega FreeFlex, Multivite Gold, Multivite Woman, Multivite CD, Milestones
|
||
Company Profile
Sanofi India is one of the entities through which Sanofi operates in India. It was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited. Over the years, its name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited, Hoechst Marion Roussel Limited and Aventis Pharma Limited. Sanofi, one of the world's leading healthcare companies, and its 100% subsidiary - Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.4% of its paid-up share capital. The shares of Sanofi India Limited are quoted on the Bombay Stock Exchange and the National Stock Exchange. The company has two manufacturing sites in Ankleshwar and Goa. Sanofi India also manufactures its products through third party manufacturers. The different types of dosage forms include tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams and ointments. These products are manufactured in accordance with the same quality standards as those prevalent at its own manufacturing sites for domestic consumption and for export to Russia, the Ukraine and other CIS countries.
Business area of the company
The company is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. The company prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. The company stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
Products
Pharmaceutical products (Adenocor, Aldurazyme, AllStar, Amaryl, Apidra, Arava, Aubagio, Augeoz, Brodactam, Cardace, Caspercid, Cerezyme, Cetapin, Clexane, Cordarone, Daonil, Depakote, Fabrazyme, Fasturtec, Fludara, Frisium, Insuman, Jevtana, Lantus, Lasilactone, Lasix, Lyxumia, Metosan, M-Nem, Myoril, Myozyme, Plavix, Primacor, Renvela Sachets, Soframycin, Solian, Stilnoct, Synvisc, Targocid, Taxotere, Telsite, Thymoglobuline, Thyrogen, Toujeo, Trental, Valparin, Vinlep, Zemiglo).
Vaccines (Adacel, Avaxim, FluQuadri, Hexaxim, Imovax Polio, Menactra, Pentaxim, Shan5, Shanchol, ShanIPV, ShanTT, Shanvac-B, Stamaril, Vaxigrip)
Consumer Healthcare products (Allegra, Allegra, Allegra M, Aminofit Forte, Amino-fit, Avil, Baralgan NU, Berrycran, Buscogast, Cetgel, Collaflex, Combiflam Plus, Combiflam Suspension, Combiflam IcyHotTM, Combiflam IcyHotTM spray, CoQ 300, DePURA by Sanofi, Dulcoflex Natural, DulcoSoft Sachet, E-Cod Plus, E-Cod W, Enlarge Forte, Enterogermina, Estoven XT, Festal N, FreeFlex Forte, Icegel, Lactacyd, Macraberin M, Mega FreeFlex, Multivite Gold, Multivite Woman, Multivite CD,
Multivite-FM Omega, Novalgin NU, Phospholip TF, Primosa, Radiance H, Seacod Active, Selace Forte,
Triomega)
Milestones
| 1 Day |
|
-0.43% |
| 1 Week |
|
-1.15% |
| 1 Month |
|
-6.76% |
| 3 Month |
|
-9.89% |
| 6 Month |
|
-20.90% |
| 1 Year |
|
-16.00% |
| 2 Year |
|
-16.17% |
| 5 Year |
|
+62.21% |
| 10 Year |
|
+213.25% |
| 9 years | 2013-12 | 2014-12 | 2015-12 | 2016-12 | 2017-12 | 2018-12 | 2019-12 | 2020-12 | 2021-12 | |
| Return on Equity (%) | 20.97 | 18.70 | 20.68 | 17.43 | 16.87 | 18.18 | 18.07 | 21.39 | 44.65 | |
| Return on Capital Employed (%) | 30.75 | 26.47 | 30.96 | 27.51 | 26.38 | 28.76 | 25.75 | 29.77 | 57.98 | |
| Return on Assets (%) | 15.11 | 12.84 | 13.88 | 12.30 | 9.50 | 8.37 | 8.28 | 9.24 | 17.74 |
| Particulars | 10 years | 2012-12 Rs. Cr. | 2013-12 Rs. Cr. | 2014-12 Rs. Cr. | 2015-12 Rs. Cr. | 2016-12 Rs. Cr. | 2017-12 Rs. Cr. | 2018-12 Rs. Cr. | 2019-12 Rs. Cr. | 2020-12 Rs. Cr. | 2021-12 Rs. Cr. |
| Shh. Funds | 1,204 | 1,347 | 1,486 | 1,627 | 1,883 | 2,026 | 2,219 | 2,442 | 2,119 | 2,226 | |
| Non Curr. Liab. | 41 | 63 | 86 | 161 | 156 | 1,335 | 1,357 | 1,124 | 1,280 | 1,039 | |
| Curr. Liab. | 387 | 469 | 656 | 617 | 502 | 962 | 1,193 | 1,674 | 1,694 | 2,291 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 1,631 | 1,878 | 2,228 | 2,405 | 2,541 | 4,324 | 4,769 | 5,240 | 5,093 | 5,555 | |
| Non Curr. Assets | 803 | 931 | 965 | 1,161 | 966 | 2,519 | 2,608 | 2,141 | 2,253 | 1,876 | |
| Curr. Assets | 829 | 947 | 1,263 | 1,244 | 1,575 | 1,805 | 2,162 | 3,099 | 2,841 | 3,679 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 1,631 | 1,878 | 2,228 | 2,405 | 2,541 | 4,324 | 4,769 | 5,240 | 5,093 | 5,555 |
| Particulars | 10 years | 2013-12 Rs. Cr. | 2014-12 Rs. Cr. | 2015-12 Rs. Cr. | 2016-12 Rs. Cr. | 2017-12 Rs. Cr. | 2018-12 Rs. Cr. | 2019-12 Rs. Cr. | 2020-12 Rs. Cr. | 2021-12 Rs. Cr. | 2022-03 Rs. Cr. TTM |
| Net Sales | 1,809 | 1,977 | 2,193 | 2,367 | 2,464 | 2,771 | 3,071 | 2,902 | 2,957 | 2,939 | |
| Other Income | 58 | 64 | 51 | 66 | 81 | 90 | 94 | 90 | 75 | 73 | |
| Total Income | 1,867 | 2,042 | 2,245 | 2,433 | 2,544 | 2,861 | 3,165 | 2,992 | 3,031 | 3,011 | |
| Total Expenditure | -1,411 | -1,639 | -1,734 | -1,832 | -1,926 | -2,148 | -2,405 | -2,189 | -2,194 | -2,171 | |
| PBIDT | 456 | 403 | 511 | 602 | 618 | 713 | 759 | 803 | 837 | 840 | |
| Interest | 0 | 0 | 0 | -2 | -1 | -1 | 0 | -2 | -2 | -2 | |
| Depreciation | -92 | -97 | -113 | -119 | -102 | -103 | -100 | -82 | -67 | -57 | |
| Taxation | -123 | -109 | -159 | -176 | -189 | -229 | -186 | -200 | -313 | -352 | |
| Exceptional Items | 25 | 67 | 84 | -59 | -42 | 489 | 607 | ||||
| PAT | 265 | 264 | 322 | 304 | 326 | 381 | 414 | 478 | 944 | 1,037 | |
| Adjusted EPS | 115 | 114 | 140 | 132 | 142 | 165 | 180 | 208 | 411 | 451 |
| Particulars | 10 years | 2012-12 Rs. Cr. | 2013-12 Rs. Cr. | 2014-12 Rs. Cr. | 2015-12 Rs. Cr. | 2016-12 Rs. Cr. | 2017-12 Rs. Cr. | 2018-12 Rs. Cr. | 2019-12 Rs. Cr. | 2020-12 Rs. Cr. | 2021-12 Rs. Cr. |
| Cash Fr. Operatn. | 290 | 273 | 265 | 213 | 322 | 435 | 374 | 412 | 611 | 559 | |
| Cash Fr. Inv. | -5 | -335 | 61 | 36 | -155 | -79 | -73 | 66 | 276 | 631 | |
| Cash Fr. Finan. | -90 | -105 | -122 | -147 | -180 | -188 | -197 | -183 | -810 | -849 | |
| Net Change | 195 | -168 | 205 | 102 | -13 | 168 | 104 | 295 | 78 | 341 | |
| Cash & Cash Eqvt | 429 | 261 | 466 | 568 | 554 | 722 | 825 | 1,120 | 1,197 | 1,538 |
|
Thu, 26 May 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication Please find enclosed copies of the Notice to shareholders of the Company published today in newspapers Business Standard and Sakal.. |
|
Wed, 25 May 2022
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s) details of which are enclosed. |
|
Mon, 23 May 2022
Completion Of Dispatchment Of Postal Ballot Further to our letter dated 13th May 2022 this is to inform that the Company is seeking approval of Members of the Company through an Ordinary Resolution for appointment of Mr. Rodolfo Hrosz as Additional Director and Managing Director of the Company by way of Postal Ballot as detailed in the Postal Ballot Notice dated 26th April 2022. Please find enclosed copy of the Postal Ballot Notice together with the Explanatory Statement for your record. The Company has today 23rd May 2022 sent an e-mail through Central Depository Services (India) Limited CDSL along with the Login ID and password to the Members for e-voting who have registered their e-mail ids with Depository Participant(s) or with the Company. The voting period will commence from Tuesday 24th May 2022 IST at 9.00 a.m. and will end on Wednesday 22nd June 2022 IST at 5.00 p.m. You are requested to kindly take the above information on record |
| Fri, 27 May 2022 |
Close Within 52 Week Low Zone
|
High Decrease 1 Month
|
High Decrease 6 Months
|
| Thu, 26 May 2022 |
Higher Delivery Quantity
|
Higher Trade Quantity
|
Equities
M.F.
Sectors